Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

FORGOTTEN MOM LAUNCHES CAPITAL CAMPAIGN FOCUSING ON MOTHERS WITH ADDICTION, A DRAMATICALLY UNDERSERVED POPULATION

Forgotten Mom Inc.

In an effort to improve outcomes and better support mothers struggling with addiction, a capital campaign for Forgotten Moms is launching today in Florida. According to data collected by the National Institute of Health (NIH), 22M Americans struggle with addiction, 23M are in addiction recovery, and 45M are directly impacted by addiction. Of those checking into treatment centers, 32% are mothers. Additionally, these women need inpatient and outpatient treatment, as well as housing to keep families together and mothers supported. Historically, many women are pushed through the court system on drug charges, where they may end up in jail, separated from their children, with many children going into foster care. Dr. Anita Cocoves, from the Critical Incident Stress Management Team of the Treasure Coast in Florida says, “As we continue to see issues with the opioid epidemic and treatment, women continue to be homeless, without care, and emotionally hopeless. They desperately need treatment, education, and longer-term support to stay healthy.” Farid Dallal, Advisor to NueroPsychiatric Addiction Treatment of Port St. Lucie, Florida, has been underwriting treatment for the last five years with his own money and has spent close to $200,000 providing scholarships for treatment service and access to over 500 people. In 2016, he created the charity, non-profit Forgotten Mom, and is now raising funds to build out a new treatment and housing facility, along with longer-term resource and education supports. Dallal says, “In the past two years, we have lost three non-profits in the South Florida area who have served these women. There is nothing for them. They need a place that is safe, trustworthy, and somewhere to keep their families together. We will be providing longer term educational support as well, to prevent relapse.” The Forgotten Mom Capital Campaign seeks to raise $2.68M and will run through 2023 with a fundraiser and documentary film in development now. They continue to build awareness and services regionally, nationally, and internationally for this necessary treatment. Adriana Cottet, lead coordinator of the capital campaign, adds, “We invite everyone to donate to this critically underserved population. Our goal is to expand our services through this capital campaign and continue to serve more women and their families.” For more information, see www.forgottenmoms.org or info@forgottenmoms.org About Forgotten Mom: Forgotten Mom Inc. (FMI), is a registered (501(c)(3), non-profit initiative established in 2016 to address, support, and find help for the dramatically underserved population of mothers struggling with the disease of addiction. www.forgottenmoms.org Contact Details Farid Dallal +1 646-640-6099 info@forgottenmoms.org Company Website http://www.forgottenmoms.org

November 01, 2022 11:11 AM Eastern Daylight Time

Former Fortune 500 Healthcare Executive Joins AliMed, Inc., As Senior Vice President Of Commercial Growth And Development

AliMed, Inc.

AliMed, Inc., a Massachusetts-based medical supply manufacturer and distributor, announced today that Jeff Hastings has joined its Senior Leadership Team as the Senior Vice President of Commercial Growth and Development. In his new role, Hastings will lead AliMed’s national sales and sales support teams, spearheading commercial expansion of its product portfolio to strengthen the company’s position and market share in both the acute and post-acute care space. Additionally, Hastings will drive efforts to develop and execute programs with preferred suppliers, build on core contract positions within the GPO, federal government, and healthcare-provider segments, and enhance the customer experience. “Jeff has relentlessly proven over his more than 20 years in healthcare leadership to be a key cog in some very critical and highly strategic endeavors,” said Adam S. Epstein, CEO of AliMed. “He is superbly skilled at developing and leading high-performing sales teams with a track record for elevating companies to the next level. We are very excited to welcome Jeff and his talents to our team.” As an influential senior executive in the healthcare industry, Hastings brings decades of leadership experience to AliMed. He has led major corporate initiatives focused on strategic transformation, portfolio diversification, and revenue acceleration for long-term sustainability at some of the nation’s largest healthcare organizations, including Owens and Minor, Cardinal Health, Hill-Rom, Roche Diagnostics, and Vizient (formerly MedAssets). Most recently, Hastings was operating partner at Mountain Pacific Fund, a life sciences investment firm based in Salt Lake City. “AliMed has such a rich, mature, and robust foundation to build on,” Hastings said of AliMed’s more than 50 years in the medical products space. “There is a great sense of enormity in this opportunity, and I’m thrilled—with the support of Adam and a very dedicated AliMed team—to help bring this organization to new heights.” A native of Ohio, Hastings holds a master’s degree in Education from the University of Akron and a bachelor’s degree in Sports Medicine and Health Education from Ashland University. About AliMed AliMed, Inc. manufactures and distributes acute and post-acute medical products and devices. For over 50 years, AliMed has innovated to deliver flexible supply chain solutions with superior service and value-based products focused on the safety and productivity of the healthcare community. AliMed’s broad portfolio of products for domestic and international care providers, dealers, and distributors are designed to improve patient outcomes and experiences from “hospital to home.” Contact Details Amy Fontaine Marketing Communications +1 857-205-8264 afontaine@alimed.com Company Website https://www.alimed.com/

November 01, 2022 10:00 AM Eastern Daylight Time

Image

Black Women, Breast Cancer and the Tests That Can Save Lives

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/13nWSPuDIAs The death rate from breast cancer continues to decline, according to a new report from the American Cancer Society. But there's a wide, worrisome gap in Black women's outcomes that remains unchanged. Black women are more likely to die from breast cancer than white women. While breast cancer incidence rates among Black and white women are close, mortality rates are markedly different, with Black women having a 41% higher death rate from breast cancer. Black women are disproportionally affected by more aggressive breast cancers because of their biology. A recent study showed that Black women are significantly more likely to have genomically High Risk tumors compared to white women, despite having the same clinical factors. This means that, all other things the same – right down to their age and the size of their tumors – the Black women in the study were more likely to have a more aggressive type of cancer. The way we can address some of these disparities is through genomic tests like MammaPrint and BluePrint, which look at 150 important genes within a tumor to estimate the risk of recurrence of that cancer. The number of genes/RNA analyzed by MammaPrint and BluePrint is higher than any other test, and captures the diversity of pathways that allows for consistent results regardless of race and ethnicity. With that information, we as physicians can make more informed decisions with our patients about what their optimal treatment plan should be. There are a few available genomic tests utilized in the clinic to guide discussions around chemotherapy benefit. One example is MammaPrint/BluePrint which are the most comprehensive tests with the most consistent results across diverse groups of patients, compared to other tests. In addition, only the BluePrint test can catch tumor subtypes that may look less dangerous, but actually behave more like triple negative breast cancer when you further classify. This is a very aggressive kind of cancer, that is over-represented among Black women. It is very important the gene expression profiling result a woman receives about her tumor is consistent and reliable regardless of her ethnicity and race, like MammaPrint and BluePrint’s. Studies showing mis-categorization of risk in minority populations due to under-representation of these patients in genomic studies and clinical trials that lead to the approval of these tests is alarming. Every woman with breast cancer has the right to know the correct and clear biological information from her tumor, regardless of her skin color, so she can make timely decisions about her treatment with her care team. For more information about gene expression profiling, including resources that can help you talk to your doctor to make sure the test being offered will work best and most accurately for you, go to Agendia.com. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 01, 2022 10:00 AM Eastern Daylight Time

Video

The Chicago School of Professional Psychology Produces 'Change Makers'

The Chicago School of Professional Psychology

The next generation of mental health professionals - some 275 “change makers” were awarded master’s and doctoral degrees last Friday at two commencement ceremonies for the Washington, DC campus of The Chicago School of Professional Psychology. The graduates enter a profession dealing with severe shortages at a time when experts say as many as one-in-five people in this country suffer from a mental disorder, and only half of those who need help can get it. In addressing the graduates, Dr. Michele Nealon, Psy.D. President of The Chicago School, said “I hope that your time as a Chicago School student has lit a fire within you – a fire to provide empathetic support for those in need. I urge you to follow your passion for service as far as you can and to light the way for others.” Joining Dr. Nealon in awarding diplomas was Dr. Donald Schultz, Ph.D, Chief Academic Officer of The Chicago School and Dr. Thelma Day, Ph.D., recipient of an honorary degree for her contributions as a counselor-educator, organizational leader and college professor. One of two student speakers was Dr. Akshaya Parthasarathi, Ph.D., a data analyst at the federal Office of Minorities and Women Inclusion, tasked by the U.S. Congress to develop policies to ensure equitable treatment of all by the nation’s financial institutions. She shared her story as an international student who is grateful to her professors and fellow students. “What looked like a distant dream for a girl from India, to study abroad in an institution like this, was made possible because of each of you. Accepting me as I am--allowing me to be different--has let me grow into a global citizen with varied experiences and stories in my pocket,” she said. “My goal is to share these experiences with people of the world, to show the power of community, and the success one can achieve when people let you be you.” Another student speaker, Dr. Bethany Patterson, Ph.D., serves as clinical director at Helianthus Positive Behavior Supports, provider of counseling services to children and families in Virginia and North Carolina. She told her story, as she sought an institution that would support her role as a military spouse and mother of three. “I needed a school that was supportive and respectful of the military lifestyle because I had unique needs,” she said. “I found a place where the learning environment is optimized by active learners with diverse cultures,” she said. “Today I embody The Chicago School’s values of innovation, service, and community-- I am giving back by creating a space to encourage other military spouses to further their education.” The Chicago School serves a majority minority student body in which two of three students identify as individuals of color. The 43-year old non-profit institution has more than 6,000 students enrolled in 30 degree and certificate programs. About The Chicago School of Professional Psychology: Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that works collaboratively to advance student success and community impact. To learn more, visit www.thechicagoschool.edu. Contact Details Vivien Hao +1 323-893-4743 vhao@thechicagoschool.edu

November 01, 2022 06:00 AM Pacific Daylight Time

VectorBuilder Raised $57 Million for Gene Delivery R&D

VectorBuilder Inc.

VectorBuilder Inc. – a global leader in gene delivery technologies – recently announced the completion of $57 million funding, which was co-led by Legend Capital. The fund will support the construction of VectorBuilder’s new Gene Delivery Research and Manufacturing Campus, and further boost the company’s R&D capabilities and global business presence. VectorBuilder was initially established in 2014 to commercialize its novel e-commerce platform that enabled researchers to design and order custom vectors online. This award-winning platform quickly gained popularity and propelled VectorBuilder to grow at an explosive pace in the ensuing years. Now VectorBuilder has become a leading provider of gene delivery solutions for both basic research and genetic medicine, and offers a full spectrum of CRO, CDMO and IP out-licensing services. VectorBuilder operates as a multinational company with branches in North America, Europe, China, Japan, South Korea, Israel and Australia, and has over 50,000 customers from over 4,000 organizations in over 80 countries around the world. VectorBuilder’s CDMO products have entered IND in many countries and received approval from the FDA and other regulatory authorities. Dr. Bruce Lahn, Chief Scientist of VectorBuilder, commented: "The fund will significantly speed up the construction of our 100,000 square meter Gene Delivery Research and Manufacturing Campus that was launched in April this year. It will also boost several major R&D projects we have undertaken such as the AAV Superbank initiative. With this funding, we can go full throttle in developing innovative gene delivery technologies that will make research more efficient, and genetic medicine more effective and affordable." About VectorBuilder Inc. VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Design Studio is a transformative innovation that allows researchers to easily design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions including advanced AAV capsid engineering capabilities, and state-of-the-art GMP facilities. With leading R&D and CDMO manufacturing capacity, the VectorBuilder team strives to provide the most effective gene delivery solutions and develop new tools for life sciences research and genetic medicine. Contact Details VectorBuilder VectorBuilder PR +1 800-517-2189 outreach@vectorbuilder.com

November 01, 2022 08:00 AM Central Daylight Time

Image

PsyKey, Inc. Announces Veteran Corporate Executive & Scientific Innovator John Gustin as Head of Global Business Development

CeCors, Inc.

CECORS, INC. (OTC PINK: CEOS) ("CeCors" or the "Company"), through its wholly owned subsidiary PsyKey Inc. an innovative wellness company, is pleased to announce the appointment of John Gustin as head of global business development. John Gustin is a veteran corporate executive and scientific innovator with more than three decades of experience building some of the fastest growing nutritional companies and brands in direct sales. Moreover, Gustin has led the effort to develop and patent numerous successful formulations for functional health and wellness products, and has authored numerous published articles related to immunology, diabetes, obesity and sports nutrition. One such patent, “# 5,914,326 Method for Promoting Weight and Fat Loss” was licensed to the former US Surgeon General Dr. C. Everett Koop. “Having John join and help guide the company, will not only give us an immense competitive advantage from a business standpoint, it opens the doors to true science backed progression and novel technologies,” said Amar Bhatal, PsyKey co-founder and president. “John’s extensive nutraceutical background, key relationships, business acumen, and his product development skills will help PsyKey strengthen existing and developing partnerships, advance strategic alliances, and expand our overall footprint in the U.S. and internationally.” “I am very excited to be joining the PsyKey team,” said Gustin. “I believe the company has a great business model and talented management team uniquely positioned to capitalize on the evolving functional wellness industry. As the industry evolves, PsyKey is poised to make a significant impact in the functional wellness market by providing a timely and cost-effective suite of brands to help consumers lead healthier, more optimized lives and routines.” As a consultant Gustin played a prominent role in the growth of numerous direct market giants, such as Nikken, Isotonix and NuSkin, providing guidance in product development and marketing strategies. He is generally credited with introducing the fat-burning, staple supplement Garcinia Cambogia to the U.S. market and helped to conduct the first human clinical studies. As a corporate member of United Sciences of America, Inc., Gustin helped the direct market company become the second fastest growing corporation in history with over $100 million in sales in its first nine months of operation. Gustin was also a founder and key executive of Evolv Health, LLC, makers of science-based functional beverages, which realized annual revenues exceeding $80 million. His discoveries and the brands he has helped develop have been viewed by millions on CNN, NBC, CBS, ABC and Fox news. About PsyKey, Inc. PsyKey, Inc. is an innovative wellness company that specializes in the development and commercialization of mycology-based entheogenic, adaptogenic, and nootropic ingredients and formulations. From functional to medicinal PsyKey, Inc. believes in the magic of mushrooms. As part of its optimal wellness strategy, PsyKey understands the importance of access to support services and healthcare professionals. Management is continuously engaged in the development of tools that will aid in removing barriers and providing inclusivity. For further information: (OTC Pink: CEOS) www.psykeyworld.com E-mail: info@psykeyworld.com Follow us on Twitter: https://twitter.com/PsyKeyworld Forward-Looking Statements: Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward- looking statements. Contact Details Sukhinderpaul Kalsi info@psykeyworld.com Company Website https://psykeyworld.com/

October 31, 2022 02:11 PM Eastern Daylight Time

This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers

Can-Fite Biopharma

The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up. Psoriasis is a chronic inflammatory skin disease caused by genetic disposition or environmental factors and is a burgeoning $16 billion global market, according to Prophecy Market Insights. Pharmaceutical companies are racing to develop new proprietary psoriasis pill options. Bristol-Myers Squibb Co. (NYSE: BMY) just saw its stock soar on news of FDA approval of oral Sotykty, joining Amgen Inc. ’s (NASDAQ: AMGN) Otezla which has been the dominant oral pill for psoriasis. But in addition to the expense of injectables and pills used to bring relief to people living with psoriasis, some of the pill options have so many side effects that many people have decided they aren’t worth ingesting. Can-Fite’s Piclidenoson Shows Positive Trial Results Another biotechnology company developing its own proprietary small-molecule drugs has presented new positive data from its Phase III COMFORT study that its Piclidenoson drug has shown a “statistically significant improvement over placebo in psoriasis patients.” Dr. Kim A. Papp, a world-renowned dermatologist, presented the news from Israel-based Can-Fite BioPharma Ltd. (NYSE American: CANF) at the 31st European Academy of Dermatology and Venerology Congress. The company reports that Piclidenoson is now advancing into a Phase III psoriasis registration trial. Developed by Papp, the protocol will be submitted this year to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for market clearance. Can-Fite is an advanced clinical-stage drug development company with a pipeline of proprietary drugs designed to help multibillion-dollar markets in treating inflammatory, cancer and liver diseases. Among its Piclidensoson drug study findings, Can-Fite reported: Its COMFORT Phase III study met its primary endpoint of superiority versus placebo at 16 weeks Patients treated with Piclidenoson showed an improving progressive response over time Piclidenoson demonstrated an excellent safety profile, overlapping the placebo-treated group. Piclidenoson, a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule drug which is orally bioavailable, has an excellent safety profile demonstrating evidence of efficacy in Phase II clinical studies, according to Can-Fite. "The safety results on Piclidenoson and its progressive effectiveness over the study period position it as unique among the current treatment options — especially given the chronic nature of psoriasis, which can necessitate long-term treatment,” Papp said. Piclidenoson Versus Otezla The Can-Fite study also found the discontinuation rate by patients taking Amgen’s Otezla was significantly higher than for Piclidenoson, based on what the company referred to as “a significantly better safety profile than Otezla including gastro intestinal-related adverse events that were only 1% for patients on Piclidenoson versus 6% for those on Otezla.” Nervous system disorders were also found to be 0.7% for people taking Piclidenoson compared to 3.3% for patients taking placebo and nearly 10% for those on Otezla. In the study, Piclidenoson demonstrated a favorable safety profile, showing results were better than the placebo-treated group, as 25.5% of patients treated with placebo had a treatment-emergent adverse event compared to only 14.8% of patients treated with Piclidenoson. The primary objective of the Can-Fite study was to evaluate the efficacy of oral Piclidenoson 2 mg or 3 mg twice daily in patients with moderate-to-severe plaque psoriasis compared with a placebo. Based on the results, analysts have set new price targets for Can-Fite, including Alliance Global Partners ($8.25), CG Capital ($6) and Dawson James Securities and H.C. Wainwright & Co. ($5). For more information on Can-Fite BioPharma, visit www.canfite.com. About Can-Fite BioPharma Ltd.Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH), and enrollment is expected to commence in a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Forward-Looking StatementsThis press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are "forward looking statements". Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to the COVID-19 pandemic and the Russian invasion of Ukraine; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the "Risk Factors" section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 24, 2022 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contact Details Motti Farbstein Motti@canfite.co.il Company Website https://www.canfite.com

October 31, 2022 09:15 AM Eastern Daylight Time

See What’s Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies!

BioRestorative Therapies, Inc.

While stem cell therapy has always been a more controversial topic, as the general public has gained more knowledge on the practice and induced pluripotent stem (iPS) cells have gained traction in place of human embryonic stem (hES) cells, the conversation has shifted more from the ethical concerns to the logistical concerns. Governments, medical facilities, and patients are concerned over the economical viability and clinical efficacy of regenerative medicine and stem cell research. Today, six of the seven leading causes of death in America are non-communicable diseases and regenerative medicine is a promising branch of science to lead the fight. A recent study conducted in 2021, highlighted the cost-effectiveness of regenerative medicine. Looking at a handful of stem cell therapies, the study showed that regenerative medicine is likely to be more impactful in cost-effectiveness compared to other conventional health technologies. The study also noted that for stem cell treatment of scoliosis, the level of cost-effectiveness was acceptable to policymakers and healthcare purchasers. It is also important to note that the best treatment for patients are ones that minimize pain while avoiding dangerous procedures like surgeries. As such, autologous cell therapy falls in this category because the treatment comes from the patient’s body, and the risks are significantly minimized. With the treatment risks minimized, the question of clinical efficacy still remains. How successful are stem cell therapies when compared to traditional treatments? Studies are showing promising results for stem cell therapies when it comes to obesity-related diseases and chronic back pain, among other non-communicable diseases. Current non-operative and surgical treatments for discongenic low back pain are leaving patients dissatisfied, whereas, stem cell regenerative therapy has shown strong results in restoring disc’s cellularity and decreasing inflammatory response in patients. With chronic low back pain impacting approximately 632 million people worldwide and as high as 68% of adults over the age of 60, finding a cure that minimizes risk and maximizes results would revolutionize treatment. Stem cells have also shown significant therapeutic potential in patients with diabetes, one of the most prevalent and deadly diseases globally. From stem cell therapies being able to regenerate into insulin-producing cells to therapies that can stimulate metabolism, the field is ripe with opportunities for patients. BioRestorative Is Making Advancements In Chronic Pain and Diabetes BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) is working on products that may be solutions in multibillion-dollar fields. Trials suggest that BRTX-100 may significantly reduce back pain and increase function in patients. There are over 60 million suffering from chronic back pain in the U.S. While the current product specifically treats disc degeneration, BioRestorative believes it shows signs of a broad range of applications within the entire musculoskeletal system (Hips, knees, shoulders and extremities). BioRestorative Therapies prides itself on doing things correctly. Its BRTX100 product for back pain goes far beyond the all-too-common clinical practice of harvesting cells and reintroducing them to the patient without proper modification. Instead, BioRestorative Therapies expands and cultures the cells using a proprietary hypoxic treatment, where a low-oxygen environment transitions the cells to express a more potent therapeutic benefit. They also combine these cells with the patient’s own platelet lysate which acts as a fertilizer to the cells and helps deliver a more survivable cell into the harsh environment of the disc. These cells not only have a greater survival rate but show increase in anti-inflammatory properties, increased circulation and enhancement of remodeling the extracellular matrix of the disc. It also only uses autologous cells for this treatment. Autologous cells come from the patient's own body and have little to no risk that the body will reject them, increasing probability of optimal results within the biological micro environment matching process BRTX’s Brown Fat Program, Thermostem, has highly promising results in the treatment of obesity and related metabolic diseases. Obesity affects over 40% of Americans, and BioRestorative is developing a novel stem-cell population — brown adipose tissue — that shows signs of stimulating metabolism and reducing excess fat. Close cooperation with the FDA is also important to BioRestorative, as the external oversight serves as a guarantor of product quality and efficacy. FDA approval also helps drive down the cost of these therapies for patients, as insurance companies are more willing to partially or fully cover the cost of FDA-approved medicines. To learn more about BioRestorative, visit its website. BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Investor Relations ir@biorestorative.com Company Website https://www.biorestorative.com/

October 31, 2022 08:15 AM Eastern Daylight Time

KOL Webinar on Genetic Blindness Points to Promise of Kiora’s Pioneering Solution--Clinical Data in Q1

Kiora Pharmaceuticals

Retinitis pigmentosa (RP) is a cluster of genetic eye diseases that damage the retina, the light-sensitive layer of the eye. It typically affects people in their teens or 20s, although some variations initiate in children as young as 8. There is currently no cure for the disease, and it inevitably leads to total blindness. Stonegate Healthcare recently hosted an event focusing on the disease. “ Battling Blindness in Retinitis Pigmentosa: A Discussion of Disease & the Pipeline of Hope ” featured three speakers: Ben Shaberman of the Foundation Fighting Blindness, who provided a patient perspective, retinitis pigmentosa specialist Dr. Christine Kay, an inherited retinal disease specialist and Kiora Pharmaceuticals Inc.’s Chief Development Officer, Dr. Eric Daniels. A Simple But Elegant Solution RP has been a difficult disease for practitioners to tackle, and the U.S. Food and Drug Administration (FDA) has not approved any treatments to date specifically indicated for the condition. In many cases, the disease is diagnosed only after vision loss initiates. According to Dr. Kay, mutations in more than 65 genes can cause RP and whilst gene therapy approaches offer promise to addressing RP, the FDA would have to essentially approve 65 unique gene therapy treatments to address all the patients with RP. Timing of diagnosis of RP may also present challenges, and for many patients, it may be too late to qualify for gene therapy treatment. Kiora Pharmaceuticals Inc. (NASDAQ: KPRX) is a pharmaceutical company specializing in treating eye diseases with high unmet need. During the webinar, Dr. Daniels talked about the company’s novel treatment, KIO-301, which is in Phase 1b clinical trials. The study is expected to generate interim data before the end of this year, with top line results planned for the first quarter of 2023. Dr. Daniels describes KIO-301 as a “simple but elegant solution” to RP. KIO-301 does not focus on the photoreceptors in the eye, which die in patients with RP, but instead turns its attention to the retinal ganglion cell (RGC – the cells that comprise the optic nerve). RGCs are still viable and functional in RP patients — it’s the photoreceptors (rods and cones) that are failing. KIO-301 specifically enters the RGCs in the eye and makes these cells light sensitive. It is the hope that KIO-301 can restore significant visual functionality in patients with vision loss due to RP. The treatment does not interfere with native functional vision, which also makes it a potentially viable treatment for patients with less-advanced RP. RP specialist Dr. Kay is hopeful and excited about Kiora’s clinical trials. Patients Have Passion and Urgency For Treatment Mr. Shaberman provided the patient’s perspective, indicating that people with RP are passionate about finding a treatment to address their blindness and are willing to participate in early stage clinical research of novel therapies to find one. Dr. Daniels said Kiora has a long list of patients from around the world who would like to be part of the company’s clinical trials. What sets KIO-301 apart from other potential therapies, including gene therapy alternatives, is the ease of treatment. Dr. Kay said she is interested in KIO-301 because it is potentially safe, easy to administer and a reasonable approach to vision restoration. KIO-301 will be administered intravitreally, allowing most any ophthalmologists the capability to provide the treatment with no need for more invasive and expensive surgeries. The risk of infection is extremely low compared to other routes of administrations. “For patients with RP, even partial restoration of their vision can be life-changing”, Mr. Shaberman said. “RP is an emotionally burdensome disease for patients and their families. KIO-301 gives hope to patients who are eagerly awaiting a solution to their blindness.” To watch a recording of the event, click here. Click here for more information on Kiora Pharmaceuticals Kiora Pharmaceuticals, Inc. (Kiora) is an ophthalmic specialty pharmaceutical company that develops therapies for the treatment of different types of eye diseases. Publicly traded on the NASDAQ under KPRX, our mission is to help patients improve their ocular health and restore vision. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading "Risk Factors" contained in Kiora's Amendment No. 1 to Annual Report on Form 10-K/A filed with the SEC on July 7, 2022 or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law. Contact Details Thomas Redington tredington@redingtoninc.com Company Website https://kiorapharma.com/

October 31, 2022 08:01 AM Eastern Daylight Time

1 ... 195 196 197 198 199 ... 308